In this article, we will list the Top 5 Small Cap Stocks With Huge Growth Potential. Please visit Top 10 Small Cap Stocks With Huge Growth Potential if you would like to see the extended list and the methodology behind it.

5. National Vision Holdings, Inc. (NASDAQ:EYE)

Stock Upside: 74.52%

Market Capitalization: $1.37 billion

Number of Hedge Fund Holders: 28

National Vision Holdings, Inc. (NASDAQ:EYE) is one of the top small cap stocks with huge growth potential. On May 13, National Vision Holdings, Inc. (NASDAQ:EYE) reported its Q1 2026 financial results and stated that revenue came in at $543.9 million, up 6.6% year over year.

The CFO, Chris Laden, explained that the revenue growth came on the back of a 5.1% increase in average customer spend. However, per Laden, overall customer traffic declined 1.2%, as self-pay customers visited stores less frequently, a trend the CFO attributed to a volatile macro backdrop, including early-quarter winter storms and shifting consumer sentiment.

Adjusted EPS came in at $0.45, well ahead of the $0.43 that analysts expected. It was also higher than the $0.34 posted in Q1 2025. The CEO, Alex Wilkes, attributed the earnings beat to aggressive cost control measures the company undertook during the quarter. For example, lower payroll and advertising costs reduced selling, general and administrative expenses by 200 basis points as a percentage of revenue, Wilkes told investors on the earnings call.

The executives also highlighted the expansion of National Vision’s military partnership with the Army and Air Force Exchange Service (AAFES). Effective April 1, the company added 20 new optical locations on military bases, which made it the sole optical provider on all US Army and Air Force bases. This also brought its total AAFES footprint to 72 locations. Management noted this does not materially change 2026 financial projections.

National Vision Holdings, Inc. (NASDAQ:EYE) is an optical retail company. It provides eye exams, prescription eyewear, contact lenses, and vision care services through brands such as America’s Best Contacts & Eyeglasses and Eyeglass World.

4. Harrow, Inc. (NASDAQ:HROW)

Stock Upside: 74.67%

Market Capitalization: $1.31 billion

Number of Hedge Fund Holders: 22

Harrow, Inc. (NASDAQ:HROW) is one of the top small cap stocks with huge growth potential. On May 13, Cantor Fitzgerald analyst Steve Seedhouse lowered his price target on Harrow, Inc. (NASDAQ:HROW) from $91 to $88, while keeping his Overweight rating intact. The analyst made the move in response to Harrow’s downward revision to its near-term revenue expectations for VEVYE, the company’s flagship dry eye drug.

Harrow shared its Q1 2026 results on May 11. The company’s quarterly revenue came in at $44.2 million. Although the figure was lower than the $47.8 million in Q1 2025, management explained that the decline wasn’t too significant because it was largely due to a one-time $8 million gross-to-net revenue adjustment. This adjustment was linked to new VEVYE commercial coverage for high-deductible plan patients who surged beyond initial demand models.

The company detailed that VEVYE posted record new and total prescriptions despite an 18% decline in the overall branded dry eye market. Unit demand for IHEEZO, the company’s product for ocular anesthesia, rose 18% year over year, and 136% year over year for TRIESENCE.

Analyst Steve Seedhouse’s thesis dwelled more on VEVYE because this is Harrow’s flagship product. The analyst pointed to the one-time $8 million gross-to-net revenue adjustment and noted that it created a pricing pressure that hit Q1 revenue but is not expected to recur. For that reason, he cut revenue expectations for the product, and by extension, convinced him to adjust the price target.

Harrow, Inc. (NASDAQ:HROW) is an ophthalmic pharmaceutical company that develops and markets medicines for eye care treatments. Its portfolio includes products for glaucoma, dry eye disease, post-surgical care, and other ophthalmic conditions.

3. Intapp, Inc. (NASDAQ:INTA)

Stock Upside: 74.91%

Market Capitalization: $1.54 billion

Number of Hedge Fund Holders: 25

Intapp, Inc. (NASDAQ:INTA) is one of the top small cap stocks with huge growth potential. On May 5, Intapp, Inc. (NASDAQ:INTA) reported its Q3 FY2026 results where revenue reached $146.0 million, up 13% year over year and slightly ahead of the $143.9 million analyst consensus.

The report shows that the growth was primarily driven by the company’s cloud transition. That is, SaaS revenue surged 27% to $107.9 million, while legacy on-premise license revenue fell from $31.7 million to $24.8 million. The executives explained on the earnings call that this shift is evidence of the company growing its higher-quality recurring revenue while shedding lower-quality one-time license income.

Non-GAAP diluted EPS came in at $0.29, beating the forecasted $0.28. Management said the difference arose from revenue growth and improving operating leverage.

According to the report, the quarter’s biggest news was the formal launch of Celeste. This is Intapp’s agentic AI platform designed to handle multi-step, compliance-sensitive workflows across an entire professional firm. It targets what the company estimates is a $30+ billion addressable market across legal, accounting, consulting, and capital markets firms.

John Hall, Intapp’s Chairman and CEO, explained on the earnings call that Celeste “works as a standalone platform and as a context and compliance layer that makes other leading AI tools more effective inside a firm.” “We are re-architecting our core business applications to run as expert agents powered by Celeste,” he added.

Intapp, Inc. (NASDAQ:INTA) is a cloud software company. It provides AI-powered solutions for professional and financial services firms, including law firms, accounting companies, consulting firms, and investment banks.

2. Enovis Corporation (NYSE:ENOV)

Stock Upside: 82.98%

Market Capitalization: $1.33 billion

Number of Hedge Fund Holders: 34

Enovis Corporation (NYSE:ENOV) is one of the top small cap stocks with huge growth potential. On May 19, Enovis Corporation (NYSE:ENOV) disclosed in an SEC filing that its shareholders approved five proposals, among them being an amendment to the company’s 2020 Omnibus Incentive Plan.

The amendment expands the pool of shares available for employee equity awards and significantly raises the compensation ceiling for independent board directors. It authorized an additional 3,650,000 shares of common stock for issuance under the 2020 plan. The amendment also raises the annual compensation cap for each independent director from $350,000 to $750,000. An exception allows the cap to reach up to 200% of the new $750,000 limit.

Separately, on May 7, Enovis reported its Q1 2026 financial results and said that it earned $589.2 million in revenue. The figure was 5.4% higher than in Q1 2025 and surpassed the $573 million analyst consensus. Non-GAAP adjusted EPS was $0.89 compared to $0.81 that Wall Street expected.

Ben Berry, Enovis CFO, told investors on the earnings call that the company revised its non-GAAP definitions following an SEC comment letter process. They removed the historical adjustment for inventory step-up charges related to the Lima acquisition.

Management maintained its outlook for revenue of $2.31-$2.37 billion, adjusted EBITDA of $425-$435 million, adjusted EPS of $3.52-$3.73, and free cash flow conversion above 25%.

Enovis Corporation (NYSE:ENOV) is a medical technology company. It develops orthopedic and rehabilitation products, including surgical implants, braces, recovery systems, and digital healthcare solutions. The company serves healthcare providers and patients through its Reconstruction and Prevention & Recovery segments.

1. Huron Consulting Group Inc. (NASDAQ:HURN)

Stock Upside: 98.51%

Market Capitalization: $1.72 billion

Number of Hedge Fund Holders: 24

Huron Consulting Group Inc. (NASDAQ:HURN) is one of the top small cap stocks with huge growth potential. On May 5, Huron Consulting Group Inc. (NASDAQ:HURN) reported its Q1 2026 financial results in which it delivered record revenue before RBR of $443.7 million. The revenue was up 12.1% year over year and exceeded the analyst consensus of $438.2 million. Of that growth, $19.3 million came from acquisitions completed in late 2024.

According to the report, the Healthcare segment carried much of the weight with $225.2 million in income, which the company measures as revenues before reimbursable expenses, or RBR. The RBR growth was possible because of strong client demand for performance improvement, revenue cycle management, financial advisory, and strategy services.

Adjusted EPS reached $1.73, well ahead of the $1.61 analyst consensus and up 3% year over year. The report also noted that adjusted EBITDA rose 21.9% to $50.6 million, which lifted the adjusted EBITDA margin to 11.4% of RBR from 10.5% a year ago. John Kelly, the CFO, said on the earnings call that this improvement came despite a higher effective tax rate. To him, this is evidence that the underlying earnings quality was stronger than the headline growth implies.

Kelly concluded his session of the earnings call by telling investors that management fully reaffirmed the company’s outlook. That means the expected RBR remains in the $1.78-$1.86 billion range, 14.5%-15.0% of RBR for adjusted EBITDA margin, and $8.35-$9.15 for adjusted EPS.

Huron Consulting Group Inc. (NASDAQ:HURN) is a professional services firm. It provides management consulting, advisory, and digital transformation solutions primarily to healthcare organizations, higher education institutions, and commercial businesses.

READ NEXT: Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks and Top 10 Stocks to Buy for Long Term.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.